The University of Southampton
University of Southampton Institutional Repository

Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial

Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial
Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial

BACKGROUND: Transarterial chemoembolisation (TACE) is the standard of care for patients with intermediate stage hepatocellular carcinoma, while the multikinase inhibitor sorafenib improves survival in patients with advanced disease. We aimed to determine whether TACE with sorafenib improves progression-free survival versus TACE with placebo.

METHODS: We did a multicentre, randomised, placebo-controlled, phase 3 trial (TACE 2) in 20 hospitals in the UK for patients with unresectable, liver-confined hepatocellular carcinoma. Patients were eligible if they were at least aged 18 years, had Eastern Cooperative Oncology Group performance status of 1 or less, and had Child-Pugh A liver disease. Patients were randomised 1:1 by computerised minimisation algorithm to continuous oral sorafenib (400 mg twice-daily) or matching placebo combined with TACE using drug-eluting beads (DEB-TACE), which was given via the hepatic artery 2-5 weeks after randomisation and according to radiological response and patient tolerance thereafter. Patients were stratified according to randomising centre and serum α-fetoprotein concentration (<400 ng/mL and ≥400 ng/mL). Only the trial coordinator was unmasked to treatment allocation before patient progression during the study. The primary endpoint was progression-free survival defined as the interval between randomisation and progression according to Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST v1.1) or death due to any cause, and was analysed by intention-to-treat. Safety was analysed by intention-to-treat. The trial has been completed and the final results are reported. The trial is registered at EudraCT, number 2008-005073-36, and ISRCTN, number ISRCTN93375053.

FINDINGS: Between Nov 4, 2010, and Dec 7, 2015, the trial enrolled 399 patients and was terminated after a planned interim futility analysis. 86 patients failed screening and 313 remaining patients were randomly assigned: 157 to sorafenib and 156 to placebo. The median daily dose was 660 mg (IQR 389·2-800·0) sorafenib versus 800 mg (758·2-800·0) placebo, and median duration of therapy was 120·0 days (IQR 43·0-266·0) for sorafenib versus 162·0 days (70·0-323·5) for placebo. There was no evidence of difference in progression-free survival between the sorafenib group and the placebo group (hazard ratio [HR] 0·99 [95% CI 0·77-1·27], p=0·94); median progression-free survival was 238·0 days (95% CI 221·0-281·0) in the sorafenib group and 235·0 days (209·0-322·0) in the placebo group. The most common grade 3-4 adverse events were fatigue (29 [18%] of 157 patients in the sorafenib group vs 21 [13%] of 156 patients in the placebo group), abdominal pain (20 [13%] vs 12 [8%]), diarrhoea (16 [10%] vs four [3%]), gastrointestinal disorders (18 [11%] vs 12 [8%]), and hand-foot skin reaction (12 [8%] and none). At least one serious adverse event was reported in 65 (41%) of 157 patients in the sorafenib group and 50 (32%) of 156 in the placebo group, and 181 serious adverse events were reported in total, 95 (52%) in the sorafenib group and 86 (48%) in the placebo group. Three deaths occurred in each group that were attributed to DEB-TACE. Four deaths were attributed to study drug; three in the sorafenib group and one in the placebo group.

INTERPRETATION: The addition of sorafenib to DEB-TACE does not improve progression-free survival in European patients with hepatocellular carcinoma. Alternative systemic therapies need to be assessed in combination with TACE to improve patient outcomes.

FUNDING: Bayer PLC and BTG PLC.

Journal Article
2468-1253
565-575
Meyer, Tim
28c8fc8e-873f-4278-9443-cb7c9f9f487f
Fox, Richard
c4e71055-d178-4d22-a758-26d3a441cc61
Ma, Yuk Ting
77151b25-329f-4275-9476-c183602b72af
Ross, Paul J.
beeaf105-3a23-47dc-a9e6-23cbebf3f4c5
James, Martin W
046304a3-9678-4307-9d86-bbfa94b6fd4d
Sturgess, Richard
ab3ca225-40c6-4efa-ba9b-d5e389bef7d3
Stubbs, Clive
03d81c31-fd9f-407f-bec8-ebdc5821d2ec
Stocken, Deborah D.
cbeab3e4-75ec-461b-a2fa-011278796486
Wall, Lucy
ca544bbc-6662-4df6-9a5c-7abb088ab64f
Watkinson, Anthony
e7b8d4ea-0de3-40bf-9e9b-57a1fb6ca57d
Hacking, Nigel
fdc70f9c-e9d6-485c-a53d-e6988fa75cb0
Evans, T.R. Jeffry
184e6cd9-5cb7-4043-ad46-f60eb8d247a8
Collins, Peter
580e9a16-a6e4-4466-8a36-6db713f716c4
Hubner, Richard A.
aeaa2faf-1c3f-4bdc-aba2-ea9f217e19c3
Cunningham, David
c40c8fe4-7eac-4b98-aaa5-b866da1e32ab
Primrose, John Neil
d85f3b28-24c6-475f-955b-ec457a3f9185
Johnson, Philip J.
e926deac-dbac-4455-a6ab-57aa8faed6d4
Palmer, Daniel H.
30c22255-e50c-422e-85a1-853ae75ff2b8
Meyer, Tim
28c8fc8e-873f-4278-9443-cb7c9f9f487f
Fox, Richard
c4e71055-d178-4d22-a758-26d3a441cc61
Ma, Yuk Ting
77151b25-329f-4275-9476-c183602b72af
Ross, Paul J.
beeaf105-3a23-47dc-a9e6-23cbebf3f4c5
James, Martin W
046304a3-9678-4307-9d86-bbfa94b6fd4d
Sturgess, Richard
ab3ca225-40c6-4efa-ba9b-d5e389bef7d3
Stubbs, Clive
03d81c31-fd9f-407f-bec8-ebdc5821d2ec
Stocken, Deborah D.
cbeab3e4-75ec-461b-a2fa-011278796486
Wall, Lucy
ca544bbc-6662-4df6-9a5c-7abb088ab64f
Watkinson, Anthony
e7b8d4ea-0de3-40bf-9e9b-57a1fb6ca57d
Hacking, Nigel
fdc70f9c-e9d6-485c-a53d-e6988fa75cb0
Evans, T.R. Jeffry
184e6cd9-5cb7-4043-ad46-f60eb8d247a8
Collins, Peter
580e9a16-a6e4-4466-8a36-6db713f716c4
Hubner, Richard A.
aeaa2faf-1c3f-4bdc-aba2-ea9f217e19c3
Cunningham, David
c40c8fe4-7eac-4b98-aaa5-b866da1e32ab
Primrose, John Neil
d85f3b28-24c6-475f-955b-ec457a3f9185
Johnson, Philip J.
e926deac-dbac-4455-a6ab-57aa8faed6d4
Palmer, Daniel H.
30c22255-e50c-422e-85a1-853ae75ff2b8

Meyer, Tim, Fox, Richard, Ma, Yuk Ting, Ross, Paul J., James, Martin W, Sturgess, Richard, Stubbs, Clive, Stocken, Deborah D., Wall, Lucy, Watkinson, Anthony, Hacking, Nigel, Evans, T.R. Jeffry, Collins, Peter, Hubner, Richard A., Cunningham, David, Primrose, John Neil, Johnson, Philip J. and Palmer, Daniel H. (2017) Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. The Lancet Gastroenterology & Hepatology, 2 (8), 565-575. (doi:10.1016/S2468-1253(17)30156-5).

Record type: Article

Abstract

BACKGROUND: Transarterial chemoembolisation (TACE) is the standard of care for patients with intermediate stage hepatocellular carcinoma, while the multikinase inhibitor sorafenib improves survival in patients with advanced disease. We aimed to determine whether TACE with sorafenib improves progression-free survival versus TACE with placebo.

METHODS: We did a multicentre, randomised, placebo-controlled, phase 3 trial (TACE 2) in 20 hospitals in the UK for patients with unresectable, liver-confined hepatocellular carcinoma. Patients were eligible if they were at least aged 18 years, had Eastern Cooperative Oncology Group performance status of 1 or less, and had Child-Pugh A liver disease. Patients were randomised 1:1 by computerised minimisation algorithm to continuous oral sorafenib (400 mg twice-daily) or matching placebo combined with TACE using drug-eluting beads (DEB-TACE), which was given via the hepatic artery 2-5 weeks after randomisation and according to radiological response and patient tolerance thereafter. Patients were stratified according to randomising centre and serum α-fetoprotein concentration (<400 ng/mL and ≥400 ng/mL). Only the trial coordinator was unmasked to treatment allocation before patient progression during the study. The primary endpoint was progression-free survival defined as the interval between randomisation and progression according to Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST v1.1) or death due to any cause, and was analysed by intention-to-treat. Safety was analysed by intention-to-treat. The trial has been completed and the final results are reported. The trial is registered at EudraCT, number 2008-005073-36, and ISRCTN, number ISRCTN93375053.

FINDINGS: Between Nov 4, 2010, and Dec 7, 2015, the trial enrolled 399 patients and was terminated after a planned interim futility analysis. 86 patients failed screening and 313 remaining patients were randomly assigned: 157 to sorafenib and 156 to placebo. The median daily dose was 660 mg (IQR 389·2-800·0) sorafenib versus 800 mg (758·2-800·0) placebo, and median duration of therapy was 120·0 days (IQR 43·0-266·0) for sorafenib versus 162·0 days (70·0-323·5) for placebo. There was no evidence of difference in progression-free survival between the sorafenib group and the placebo group (hazard ratio [HR] 0·99 [95% CI 0·77-1·27], p=0·94); median progression-free survival was 238·0 days (95% CI 221·0-281·0) in the sorafenib group and 235·0 days (209·0-322·0) in the placebo group. The most common grade 3-4 adverse events were fatigue (29 [18%] of 157 patients in the sorafenib group vs 21 [13%] of 156 patients in the placebo group), abdominal pain (20 [13%] vs 12 [8%]), diarrhoea (16 [10%] vs four [3%]), gastrointestinal disorders (18 [11%] vs 12 [8%]), and hand-foot skin reaction (12 [8%] and none). At least one serious adverse event was reported in 65 (41%) of 157 patients in the sorafenib group and 50 (32%) of 156 in the placebo group, and 181 serious adverse events were reported in total, 95 (52%) in the sorafenib group and 86 (48%) in the placebo group. Three deaths occurred in each group that were attributed to DEB-TACE. Four deaths were attributed to study drug; three in the sorafenib group and one in the placebo group.

INTERPRETATION: The addition of sorafenib to DEB-TACE does not improve progression-free survival in European patients with hepatocellular carcinoma. Alternative systemic therapies need to be assessed in combination with TACE to improve patient outcomes.

FUNDING: Bayer PLC and BTG PLC.

Text
TACE 2 Revision 2 Clean - Accepted Manuscript
Download (227kB)
Text
Sorafenib-in-combination-with-transarterial-chemoembolisat_2017_The-Lancet-G - Version of Record
Download (455kB)

More information

Accepted/In Press date: 22 June 2017
e-pub ahead of print date: 23 June 2017
Published date: August 2017
Keywords: Journal Article

Identifiers

Local EPrints ID: 413124
URI: http://eprints.soton.ac.uk/id/eprint/413124
ISSN: 2468-1253
PURE UUID: f37bf394-9f7d-48f1-b7fa-5c00540163e8
ORCID for John Neil Primrose: ORCID iD orcid.org/0000-0002-2069-7605

Catalogue record

Date deposited: 15 Aug 2017 16:30
Last modified: 11 May 2024 04:01

Export record

Altmetrics

Contributors

Author: Tim Meyer
Author: Richard Fox
Author: Yuk Ting Ma
Author: Paul J. Ross
Author: Martin W James
Author: Richard Sturgess
Author: Clive Stubbs
Author: Deborah D. Stocken
Author: Lucy Wall
Author: Anthony Watkinson
Author: Nigel Hacking
Author: T.R. Jeffry Evans
Author: Peter Collins
Author: Richard A. Hubner
Author: David Cunningham
Author: Philip J. Johnson
Author: Daniel H. Palmer

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×